Delving into the Latest Updates on Jieku (Shanghai) Biomedical Research Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Infectious Diseases

Urogenital Diseases

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Fusion protein	1

Top 5 Target	Count

IL-17R(Interleukin-17 receptor)	1

主要目的评价 JLM019 注射液治疗 AST 和 HL/NHL 患者的安全性和耐受性。次要目的初步观察 JLM019 注射液对 AST 和 HL/NHL 患者的疗效；评价 JLM019 注射液的药代动力学特征（PK）；评价 JLM019 注射液的药效动力学特征（PD）；评估 JLM019 注射液多次给药的免疫原性；探索与 JLM019 注射液相关的生物标志物。

[Translation]

Primary Objective: To evaluate the safety and tolerability of JLM019 injection in patients with AST and HL/NHL. Secondary Objectives: To preliminarily observe the efficacy of JLM019 injection in patients with AST and HL/NHL; to evaluate the pharmacokinetic (PK) characteristics of JLM019 injection; to evaluate the pharmacodynamic (PD) characteristics of JLM019 injection; to assess the immunogenicity of multiple-dose JLM019 injection; and to explore biomarkers associated with JLM019 injection.

Start Date07 Jan 2026

Sponsor / Collaborator

Jieke (Tianjin) Biomedical Co Ltd

[+1]

CTR20241578

/ CompletedPhase 1

评价JL18008注射液在健康成年受试者/HIV免疫重建不良患者中的药代动力学、药效动力学、安全性的随机、双盲、安慰剂对照的I/Ⅱ期临床研究

[Translation] A randomized, double-blind, placebo-controlled phase I/II clinical study to evaluate the pharmacokinetics, pharmacodynamics, and safety of JL18008 injection in healthy adult subjects/patients with poor HIV immune reconstitution

Ia期主要目的：评价JL18008注射液在健康成年受试者中单次肌肉注射的安全性、耐受性。次要目的：评价JL18008注射液在健康成年受试者中单次肌肉注射的药代动力学（PK）特征；初步评价JL18008注射液在健康成年受试者中单次肌肉注射的药效动力学（PD）特征；初步评价JL18008注射液在健康成年受试者中单次肌肉注射的免疫原性。

[Translation]

Phase Ia Main purpose: To evaluate the safety and tolerability of a single intramuscular injection of JL18008 injection in healthy adult subjects. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of a single intramuscular injection of JL18008 injection in healthy adult subjects; To preliminarily evaluate the pharmacodynamic (PD) characteristics of a single intramuscular injection of JL18008 injection in healthy adult subjects; To preliminarily evaluate the immunogenicity of a single intramuscular injection of JL18008 injection in healthy adult subjects.

Start Date13 Jun 2024

Sponsor / Collaborator

Jieku (Shanghai) Biomedical Research Co., Ltd.

CTR20223129

/ CompletedPhase 1

JL14001注射液在健康成年受试者中单次给药、剂量递增的药代动力学、药效学、安全性、耐受性的I期临床研究

[Translation] A phase I clinical study of the pharmacokinetics, pharmacodynamics, safety and tolerability of JL14001 injection in healthy adult subjects with a single dose and increasing dose

主要目的：评价JL14001注射液在健康成年受试者中的安全性、耐受性。次要目的：评价JL14001注射液在健康成年受试者中的药代动力学（PK）特征；初步评价JL14001注射液在健康成年受试者中的药效动力学（PD）特征；初步评价JL14001注射液在健康成年受试者中的免疫原性；初步评估短效EPO产品-益比奥及长效EPO产品-耐斯宝分别与JL14001注射液的剂量换算关系和PD特征。

[Translation]

Primary purpose: Evaluate the safety and tolerability of JL14001 injection in healthy adult subjects. Secondary purpose: Evaluate the pharmacokinetic (PK) characteristics of JL14001 injection in healthy adult subjects; Preliminary evaluation of the pharmacodynamic (PD) characteristics of JL14001 injection in healthy adult subjects; Preliminary evaluation of the immunogenicity of JL14001 injection in healthy adult subjects; Preliminary evaluation of the dose conversion relationship and PD characteristics of the short-acting EPO product - EPIAO and the long-acting EPO product - Nicebo with JL14001 injection respectively.

Start Date07 Apr 2023

Sponsor / Collaborator

Jieku (Shanghai) Biomedical Research Co., Ltd.

100 Clinical Results associated with Jieku (Shanghai) Biomedical Research Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jieku (Shanghai) Biomedical Research Co., Ltd.

Login to view more data

100 Deals associated with Jieku (Shanghai) Biomedical Research Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jieku (Shanghai) Biomedical Research Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Other

Login to view more data